Table 3.
In-hospital management and outcomes among patients admitted with ACS.
| Management | STEMI | NSTE-ACS | Total | p-value |
|---|---|---|---|---|
| No. of patients | n = 111 | n = 70 | N = 181 | |
| Within the first 24 h, n (%) | ||||
| Aspirin | 92 (82.9) | 48 (68.6) | 140 (77.3) | 0.025* |
| DAPTa | 88 (79.3) | 44(62.9) | 132 (72.9) | 0.015* |
| Statins | 90 (81.1) | 45 (64.3) | 135 (74.6) | 0.011* |
| Beta-blockers | 81 (73.0) | 41(58.6) | 122 (67.4) | 0.044* |
| ACEIs/ARBs | 73 (65.8) | 38 (54.3) | 111 (61.3) | 0.112 |
| During hospital stay, n (%) | ||||
| Aspirin | 111 (100.0) | 69 (98.6) | 180 (99) | 0.207 |
| DAPTa | 103 (92.8) | 63 (90.0) | 166 (92) | 0.507 |
| Statins | 109 (98.2) | 69 (98.6) | 178 (98) | 0.848 |
| Beta-blockers | 90 (81.1) | 56 (80.0) | 146 (81) | 0.858 |
| ACEIs/ARBs | 84 (75.7) | 47 (67.1) | 131 (72) | 0.211 |
| Any heparin | 86 (77.5) | 52 (74.3) | 138 (76) | 0.623 |
| Nitrates | 32 (28.8) | 21 (30.0) | 53 (29) | 0.818 |
| Morphine | 54 (48.6) | 22 (31.4) | 76 (42.0) | 0.022* |
| Diuretics | 59 (53.2) | 38 (34.2) | 97 (53.6) | 0.882 |
| Reperfusion therapy | ||||
| Fibrinolytic medications | 0 | 0 | 0 | – |
| PCIb | 10 (9) | 3 (3.4) | 13 (7.2) | 0.231 |
| No. of patients | n = 82 | n = 62 | N = 144 | |
| Discharge medications, n (%) | ||||
| Aspirin | 82 (100.0) | 58 (93.5) | 140 (97.2) | 0.015* |
| Clopidogrel | 69 (84.1) | 40 (64.5) | 109 (75.7) | 0.014* |
| Beta-blockers | 72 (87.8) | 48 (77.4) | 120 (83.3) | 0.511 |
| ACEIs/ARBs | 67 (81.7) | 42 (67.7) | 109 (75.7) | 0.379 |
| Statin | 80 (97.6) | 58 (93.5) | 138 (95.8) | 0.915 |
| Spironolactone | 17 (20.7) | 12 (19.4) | 29 (20.1) | 0.817 |
| In-hospital outcomes, n (%) | ||||
| All-cause mortality | 29 (26.1) | 8 (11.4) | 37 (20.4) | 0.017 |
| Cardiovascular deathc | 22 (19.8) | 5 (7.1) | 27 (14.9) | 0.020 |
| Hospital stay (days)d | 12.4 ± 7.0 | 11.1 ± 5.1 | 12.4 ± 6.3 | 0.903 |
| 30-day mortality | 35 (31.5) | 11 (15.7) | 46 (25.4) | 0.017* |
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; DAPT, dual antiplatelet therapy; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
*
p < 0.05 (statistically significant).
a
Aspirin + clopidogrel.
b
All performed after 12 h of symptom onset (late reperfusion).
c
Composite of fatal cardiovascular shock, cardiac arrest, arrhythmia, acute heart failure, and myocardial infarction.
d
Expressed as the mean and standard deviation.